Special Article: The Normal Hematocrit Cardiac Trial Revisited
- 1 September 2009
- journal article
- Published by Wiley in Seminars in Dialysis
- Vol. 22 (5) , 495-502
Abstract
The Normal Hematocrit Cardiac Trial (NHCT) was the first large, randomized study of patients receiving hemodialysis to examine the outcomes of treating anemia to a target hematocrit range of 42 +/- 3% versus maintaining partial correction in a range of 30 +/- 3%. The results of the NHCT and a meta-analysis adding eight subsequent trials of normalization of hematocrit/hemoglobin in chronic kidney disease (CKD) have demonstrated increased thrombovascular events and mortality associated with the higher targets. This article expands and clarifies the results of the NHCT, including data that were edited from the original publication, and highlights findings from more recent studies in the field. Paradoxically, none of the randomized trials has reported an association between higher attained hemoglobin concentration and mortality within randomized groups. Mean platelet count did not increase among the patients in the normal-hematocrit group in the NHCT or in two other large trials, CREATE and CHOIR. Exposure to high doses of erythropoietic stimulating agents and/or intravenous iron could be mediating complications in the CKD anemia-normalization studies, but post-hoc analyses to probe such potential associations have yielded conflicting results and are clearly hindered by the risk of confounding by indication. The mechanisms underlying the deleterious outcomes associated with efforts to correct renal anemia fully remain unproven.Keywords
This publication has 33 references indexed in Scilit:
- Erythropoietin Therapy, Hemoglobin Targets, and Quality of Life in Healthy Hemodialysis PatientsClinical Journal of the American Society of Nephrology, 2009
- Estimated Effect of Epoetin Dosage on Survival among Elderly Hemodialysis Patients in the United StatesClinical Journal of the American Society of Nephrology, 2009
- Use of erythropoietic stimulating agents in the setting of renal disease2009
- Erythropoietin, Iron Depletion, and Relative Thrombocytosis: A Possible Explanation for Hemoglobin-Survival Paradox in HemodialysisAmerican Journal of Kidney Diseases, 2008
- Intravenous Iron Exacerbates Oxidative DNA Damage in Peripheral Blood Lymphocytes in Chronic Hemodialysis PatientsJournal of the American Society of Nephrology, 2008
- Secondary analysis of the CHOIR trial epoetin-α dose and achieved hemoglobin outcomesKidney International, 2008
- Greater Epoetin alfa Responsiveness Is Associated With Improved Survival in Hemodialysis PatientsClinical Journal of the American Society of Nephrology, 2008
- Ferric Gluconate Is Highly Efficacious in Anemic Hemodialysis Patients with High Serum Ferritin and Low Transferrin SaturationJournal of the American Society of Nephrology, 2007
- Correction of Anemia with Epoetin Alfa in Chronic Kidney DiseaseNew England Journal of Medicine, 2006
- Prospective Study of the Immune Effects of Normalizing the Hemoglobin Concentration in Hemodialysis Patients Who Receive Recombinant Human ErythropoietinJournal of the American Society of Nephrology, 2004